Table 1 Demographics, on-arrival presentation, and treatment response by group
Variable | Total (n = 30) | Lorazepam (n = 15) | Clonazepam (n = 15) | P (MWU test) |
|---|---|---|---|---|
Median [IQR] (range) | ||||
Age (months) | 15 [10, 36] (6, 144) | 15 [10, 37] (6, 144) | 17 [11, 33] (6, 84) | 0.637 |
Weight (kg) | 11 [10,14] (6.5, 40) | 11.5 [9.5, 15] (8, 40) | 10.7 [10,, 13.7] (6.5, 25) | 0.697 |
Time elapsed between exposure and presentation (h) | 3 [5,6] (1, 72) | 5 [4,9] (2, 72) | 3 [5,6] (1, 14) | 0.377 |
Time elapsed between exposure and the development of symptoms (h) | 1 [1,2] (0.5, 24) | 1 [1,, 2.2] (0.5, 24) | 1 [1,2] (0.5, 2) | 0.275 |
Presentation on arrival | ||||
Temperature (C) | 37 [36.5, 37] (36, 37.7) | 36.9 [36.5, 37] (36, 37.3) | 37 [36.7, 37.1] (36.5, 37.5) | 0.142 |
Systolic BP (mmHg) | 90 [90, 100] (80, 110) | 92 [90, 100] (80, 110) | 90 [90, 100] (80, 110) | 0.400 |
Diastolic BP (mmHg) | 50 [50, 60] (40, 80) | 60 [50, 70] (50, 80) | 50 [50, 60] (40, 70) | 0.160 |
Heart rate (per minute) | 127 [110, 140] (90, 160) | 130 [110, 150] (92, 160) | 120 [102, 140] (90, 150) | 0.498 |
Respiratory rate (per minute) | 30 [27, 35] (16, 60) | 31[26, 35] (22, 60) | 30 [28, 34] (16, 60) | 0.667 |
Creatine phosphokinase (U/L) | 218 [148, 360] (88, 1584) | 225 [148, 461] (117, 698) | 211[126, 324] (88, 1584) | 0.697 |
Treatment response | ||||
Duration of symptoms (h) | 4 [3,5] (2, 20) | 3 [2,4] (2, 13) | 5 [3,7] (2, 20) | 0.166 |
Hospitalization period (h) | 24 [24, 48] (24, 72) | 24 [24, 48] (24, 48) | 24 [24, 42] (24, 72) | 0.525 |